Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Israeli - Kiingereza - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 1000 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israeli - Kiingereza - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 500 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israeli - Kiingereza - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

Israeli - Kiingereza - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 500 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - meropenem

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 1 grams - meropenem